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ABSTRACT  
Objectives 
To assess the cost-effectiveness of screening for open-angle glaucoma (OAG) in 
the UK; OAG is an important cause of blindness worldwide.   
Methods 
A Markov Model was developed to estimate lifetime costs and benefits of a 
cohort of patients facing, alternatively, screening or current opportunistic case 
finding strategies. Strategies, varying in how screening would be organised, (e.g. 
invitation for assessment by a glaucoma-trained optometrist (GO) or for simple 
test assessment by a technician) were developed, and allowed for the progression 
of OAG and treatment effects. Data inputs were obtained from systematic 
reviews. Deterministic and probabilistic sensitivity analyses were performed. 
Results  
Screening was more likely to be cost-effective as prevalence increased, for 40 year 
olds compared with 60 or 75 year olds, when the re-screening interval was 
greater (10 years), and for the technician strategy compared with the GO 
strategy.  For each age cohort and at prevalence levels of ≤1%, the likelihood that 
either screening strategy would be more cost-effective than current practice was 
small.  For those aged 40 ‘technician screening’ compared with current practice 
has an Incremental Cost Effectiveness Ratio (ICER) that society might be willing 
to pay when prevalence is 6% to 10% and at over 10% for 60 year olds. In the UK 
the age specific prevalence of OAG is much lower.  Screening by GO, at any age 
or prevalence level, was not associated with an ICER <£30,000.  
Conclusions 
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Population screening for OAG is unlikely to be cost-effective but could be for 
specific sub-groups at higher risk.  
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Economic evaluation, Glaucoma, Screening, cost effectiveness analysis, cost 
utility analysis. 
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1 Introduction 
Glaucoma is a progressive optic neuropathy leading to blindness if untreated. 
Worldwide, glaucoma is the leading cause of irreversible blindness and open-
angle glaucoma (OAG) accounts for about 50% of glaucoma blindness (18). In a 
developed country setting the majority of OAG cases will remain undiagnosed 
by current case finding strategies (9).  
Risk factors for developing OAG are raised intraocular pressure (IOP), increasing 
age, black ethnicity, family history of glaucoma, myopia and diabetes (9). A key 
criterion for a screening programme is that early detection leads to a better 
outcome than late detection. A systematic review (two trials, 500 patients) of 
treatment effectiveness, demonstrated that treatment reduces the risk of 
progression in early disease (16).   Population screening for OAG might allow the 
early treatment and hence reduce the incidence of visual impairment and 
blindness.  However, it is important to know if the screening for OAG is cost-
effective but existing economic evaluations are insufficient for evidence-based 
recommendations (13). The aim of this study was to model the cost-effectiveness 
of screening for OAG compared with current practice, in the UK, of opportunistic 
case finding.   
 
2 Methods 
The Model 
We developed a Markov Model (MM)(Figure 1) (7;20). Health state definitions 
(see website, Box 1) were based on the severity of binocular visual field loss, 
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adapted from a scoring system of the integrated visual field,  reported by Crabb 
and colleagues (10). 
The model structure allows individuals to enter as healthy (no OAG), and at 
varying degrees of OAG severity. Over time, healthy individuals can develop 
OAG (i.e. new incident cases), while those with OAG can develop more severe 
disease and eventual visual impairment. The treatment states refer to treated 
disease at each stage. The absorbing state in the model is death and individuals 
can move into this state from any other state within the model. 
The model allows for a cohort of the population, some with OAG, to pass 
through different strategies.  The model identifies that strategy which leads to the 
largest proportion of individuals with OAG “crossing the bridge” into treatment 
(Figure 1).  A complete version of the model can be obtained from the authors.  
Model strategies  
We considered three strategies within the model: current practice and two 
alternative screening strategies.  Current UK practice involves the opportunistic 
identification of cases by community optometrists as part of a routine eye test. 
There are many tests and configurations of testing arrangements that are 
potentially suitable for an OAG screening programme; the modelled pathways 
were determined by consensus by an expert panel.  The two alternative screening 
strategies vary in how screening would be organised. In one, individuals are 
invited for a screening examination by a glaucoma trained optometrist and 
undergo a complete glaucoma assessment involving a measure of IOP, an 
assessment of the optic nerve and a visual field test.  In the second strategy, 
individuals are invited for an automated test quantifying functional visual field 
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loss or structural damage of the optic nerve, together with a measurement of IOP, 
by a technician and individuals identified as at risk are then referred for a full 
glaucoma assessment by a glaucoma optometrist.  In all three strategies any 
individual identified as positive at the end of screening or case finding would be 
referred to an ophthalmologist for definitive diagnosis and, if necessary, 
treatment. 
Glaucoma treatments 
Once OAG is diagnosed, we have assumed that treatment would be initiated.  
There is a cascade of eye drop treatment options for each disease stage as well as 
their combination with laser or surgical treatment.  Evidence on their 
effectiveness suggested that these could be approximated by a single effect size 
but treatment might vary by OAG severity and progression rate. We assumed 
initial medical treatment by a beta blocker or prostaglandin analogue, followed   
by an additional drop of another class of medications if initial treatment was 
ineffective.  For those for whom this fails, argon trabeculoplasty or surgery 
(trabeculectomy) is the next treatment step.  In addition to medications, 
treatment involves visits to the ophthalmologist every six weeks at the beginning 
of treatment and a full assessment every six months.  After surgery the patient 
would be seen at an ophthalmology outpatient clinic at one, two, four, eight, 12, 
and 26 weeks post surgery.   
Parameter estimates used in the model 
 We obtained the model parameter estimates (Table 1) from a series of systematic 
reviews of test accuracy, epidemiology, treatment effectiveness and cost-
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effectiveness as well as other systematic, focused searches. Detailed description 
of the parameters estimates can be found in Burr and colleagues (9). 
Probabilities 
Table 1a reports the prevalence, incidence and progression of glaucoma 
parameters used.  As there were many potential target groups, each with 
different risk levels, we ran the model for a range of prevalence values, aiming to 
identify a prevalence where screening might be considered worthwhile, and thus 
the population most likely to benefit from screening.  
Data on the annual probabilities of having an eye test, by sex and age came from 
the British Household Panel Survey (BHPS) (4). We obtained screening 
acceptance data from the epidemiology review (9). 
We did not identify any studies reporting the diagnostic accuracy of current 
practice, thus we derived sensitivity and specificity estimates from Tuck and 
colleagues (23), the most appropriate, in terms of geographical coverage, number 
of patients seen and number of participating optometrists.  
The accuracy of the glaucoma optometrist testing was taken from a recent study 
by Azuara-Blanco and colleagues (6), a Scottish comparative, masked, 
performance study. Data from the Baltimore Eye Survey (19) were used for the 
estimation of the proportion of normal or OAG patients with one of the main risk 
factors for OAG, IOP ≥ 26mmHg (19). Estimation of the proportion of people able 
to perform the test (rate of indeterminancy) required for the ‘technician’ 
screening strategy came from the systematic review of screening tests (9).  The 
model used sensitivity and specificity values for the technician further test equal 
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to or greater than 0.8. As the systematic review showed that no one test or test 
combination was clearly more accurate and acceptable, we included a range of 
sensitivity and specificity values in the model, rather than modelling the 
performance of one test or combination thereof. Finally, ophthalmologist 
assessment was assumed as the reference standard.  For probabilistic sensitivity 
analysis we assumed beta distributions for all parameters except for: technician 
further test indeterminacy, sensitivity and specificity and the proportion of 
people referred for observation as glaucoma suspects by an ophthalmologist’s 
diagnostic assessment (uniform distributions).  
Costs 
Table 1b shows the cost data used (2006 pounds sterling).  We used a 2% inflation 
rate for adjustments into a common price year, where no inflation rate indices 
were available. Where no information on ranges was obtainable we assumed a 
triangular distribution and rates of 0.5 and 1.5 times the likeliest value were used 
as lower and upper limits.  We obtained the cost for the optometrist test from the 
NHS ‘sight’ test fees (3).  For the purposes of costing we assumed that the IOP 
testing used Goldmann applanation tonometry (GAT) with disposable tips, and  
that the glaucoma optometrist assessment used the same test combination as 
ophthalmologist diagnosis (a combination of IOP measurement by GAT, slit 
lamp examination, fundoscopy, and a visual field test). The cost of 
ophthalmologist diagnosis was based on the cost of two standard ophthalmology 
outpatient consultations (5) and for the observation state cost where patients 
judged at risk would be seen yearly for up to five years or until OAG was 
diagnosed.  
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 We estimated the treatment costs from a European study including data from 
194 patients, containing data for the UK by severity of glaucoma (22).  The 
likeliest value for the cost of visual impairment was taken to be the mean value of 
the last two disease stages (22) as these corresponded to the visual impairment 
category used in this study.  We assumed a triangular distribution for 
probabilistic sensitivity analysis. 
We used the NHS fees for optometrists in Scotland for the glaucoma optometrist 
assessment (2), and costs for the ‘technnican screening strategy’ from the Scottish 
Diabetic Retinopathy Screening study (1), and the screening invitation costs 
(Table 1.b) from the same study.  
Quality of life and Utilities 
We used EQ-5D utility estimates from a recent UK study involving almost 300 
participants (8),  including a subjective and objective assessment of glaucoma 
severity.  We used the objective scores for each health state for the base case and 
subjective scores in the sensitivity analysis (Table 1b).  We developed the utility 
state for visual impairment using weight data for the glaucoma severe state and 
the relative difference from Gupta and colleagues (12). We attached Beta 
distributions to these glaucoma utility weights parameters.(web site  Briggs 2006)  
We assumed that there were no differences in the utility between undiagnosed 
OAG and treated OAG at each level of severity.  
Base case analysis 
We ran the base case analysis for cohorts of 40, 60 and 75 year old males, for a 
range of prevalence values, for a lifetime horizon with screening occurring every 
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three years, and conducted from the UK National Health Service (NHS) 
perspective.   The cycle length was set at one year and a 3.5% discount rate was 
used.(web site NICE 2004)  The results are presented in incremental cost-
effectiveness ratios (ICERs).  We undertook probabilistic analyses for ranges of 
OAG prevalence from 0.1% to 10%.   
Sensitivity analysis 
One way, two-way and multiway sensitivity analyses for the main parameters 
within the model were conducted, almost all of which were combined with 
probabilistic sensitivity analysis.  
In these analyses we explored the effects of longer screening intervals (e.g. five 
and ten years) and varying the annual probability of a community optometrist 
eye test (2%, 13%, 37%) uptake rates using one-way sensitivity analysis.  We 
varied the sensitivity and specificity of the technician test within plausible ranges 
of 0.5 to 1.0 for sensitivity and 0.8 to 1.0 for specificity.  
Additionally, we performed several targeted sensitivity analyses on a 40 year old 
cohort, at a 5% (except where otherwise stated) OAG prevalence rate and a ten 
year screening interval (a combination which seemed most likely to be cost-
effective). As the group of individuals with higher OAG prevalence rate would 
have a higher chance of visiting the optometrist, we conducted an analysis 
assuming 1.5 times and twice the probability of having an eye test for current 
practice strategy. We used alternative triangular probability distributions for 
progression and incidence using lower and upper base case limits as more likely 
values.  We also explored the impact of using subjective glaucoma severity based 
health state utilities (8). We also conducted high and low cost scenario analyses.   
11 
Hernández et al. “Economic evaluation of screening for open angle glaucoma” 
Finally, we used one-way sensitivity analysis to identify threshold values for the 
annual cost of visual impairment to explore the effect of widening the 
perspective of the analysis. This final analysis was conducted for 1% and 5% 
prevalence rate of OAG. 
 
3 Results  
Table 2 reports the estimated relative cost-effectiveness by screening strategy at 
different levels of prevalence of OAG for cohorts aged 40, 60 and 75 years 
respectively.  In each analysis as prevalence increases, costs increase and QALYs 
fall for all three strategies and all age cohorts.  In each analysis at each prevalence 
level and age group considered, current practice is the least costly but also the 
least effective of the three strategies.  Adopting a ‘technician’ stategy is more 
effective but more costly than current practice and screening by a glaucoma 
optometrist is more effective but more costly than the ‘technician’ screening 
strategy. 
For each age group considered the ICER from adopting ‘technician’ screening 
compared with current practice falls as prevalence increases.  Similarly, for each 
age group considered, the ICER gained from adopting ‘glaucoma optometrist’ 
screening compared with ‘technician’ screening also falls as prevalence increases. 
In the base case analysis for a 40 year-olds cohort a ‘technician’ screening strategy 
compared with current practice has an ICER that society might be willing to pay 
when prevalence is approximately 6% to 10% (Table 2) and over 10% for a 60 
year-olds.  For a 75 year-olds cohort, current practice strategy has an ICER that 
might be considered worthwhile (Table 2) even when prevalence level is 20% 
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(not shown).  Furthermore, for no age cohort and no prevalence level is screening 
by the glaucoma optometrist instead of screening by the technician associated 
with an ICER less than £30,000. 
Sensitivity analysis performed around the base case 
The probabilistic sensitivity analysis (Table 3) indicates for every cohort group 
and at prevalence levels of 1% or less, the likelihood that any screening strategy 
would be more cost-effective than current practice is small.  At 5% prevalence for 
the 40 year-olds cohort level there is less than 50% likelihood that ‘technician’ 
screening might be considered cost-effective at a willingness to pay for a QALY 
of £30,000.  Glaucoma optometrist screening is unlikely to be considered cost-
effective. 
Increasing the screening interval reduces the ICER for each age group and each 
prevalence level, as OAG on average, progresses relatively slowly and QALY 
reduction is more than compensated for by costs reduction. Varying the annual 
uptake rates for community optometrist testing led to both cost and QALYs 
rising as uptake increased. The higher the uptake, the better the current practice 
strategy performs. The results of the sensitivity analysis on sensitivity and 
specificity of the test following the measurement of IOP in the ‘technician’ 
strategy indicate that the ICER is relatively insensitive to changes in these 
variables.   
Targeted sensitivity analyses 
Further sensitivity analysis for a 40 year old cohort, ten year screening interval 
and a 5% OAG prevalence indicated that screening with the ‘technician’ strategy 
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might be considered worthwhile (see web site Table 4a). Probabilistic sensitivity 
analysis demonstates that the uncertainty around model parameter estimates 
was important, e.g.  even though the ICER for the comparison of the ‘technician’ 
with the current practice strategy is £20,571 there is only 42% likelihood that the 
cost per QALY would be less than £20,000. 
Furthermore, sensitivity analyses on uptake of community optometrist testing 
demonstrated that the QALY gain for the current practice strategy more than 
compensates for its’ higher cost.  The ICER of the ‘technician’ strategy compared 
with current practice increased, as did the ICER for the comparison of the 
‘glaucoma optometrist’ strategy compared with the ‘technician’ strategy. 
Changes to the rate of OAG incidence did not greatly alter cost-effectiveness, 
however, as the rate of progression increased (See web site Table 4.b ’high’) then, 
the likelihood that either screening strategies could be considered cost-effective 
increased, as screening is likely to detect more cases and hence delay 
progression.  Using alternative valuations for health utilities, varying the cost of 
diagnosis by the ophthalmologist, the costs of treatment, inviting people to be 
screened or their subsequent tests had little effect on cost-effectiveness.   
The threshold analysis for the cost of visual impairment and 1% OAG prevalence 
shows the ‘technician’ strategy dominates the current practice strategy when the 
annual cost for visual impairment is around £16,000; moreover, the ICER is less 
than £30,000 if the cost of visual impairment is greater than £8,800.  For the 
‘glaucoma optometrist’ strategy to be considered cost-effective compared with 
the ‘technician’ strategy would require the annual cost of visual impairment to be 
greater than £40,000. (see web site, Figure 2)  
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4 Discussion 
We conducted a model based cost-utility analysis of the screening for OAG that 
compared technician or glaucoma optometrist based screening with current 
practice (e.g. opportunistic case finding). Data to populate this model came from 
a series of systematic reviews of the literature and incorporated extensive 
sensitivity analyses to the imprecision surrounding parameter estimates and 
other forms of uncertainty.  The distributions used to characterise the statistical 
imprecision varied by parameter but were consistent with prior experience about 
which type of distribution would be appropriate for the type and nature of the 
data available.(web site Iverson 1984, Philips 2004) Although, the best use was 
made of, in some cases, limited data, further information on the value of almost 
all parameter estimates would be useful. 
Our study suggests that general population screening is unlikely to be cost-
effective as the prevalence of OAG in the younger cohorts (estimated 0.9% at 
aged 50), most likely to enjoy the benefits of screening for longer, is too low. 
However, screening might be cost-effective for selected ‘at risk’ sub-groups.  
Targeted screening of 40 to 50 year-olds with a risk factor, (e.g. black ethnicity or 
those with a family history of glaucoma), is more likely to be cost-effective 
assuming a prevalence of OAG between 3% to 4% and a screening interval of ten 
years. These groups account for about 6% of the UK population. 
In our model costs increase as prevalence increases because a larger proportion 
of individuals in the cohort incur the costs of diagnosis and the continuing costs 
of treating the OAG.  The mean cost per person and estimated QALYs are higher 
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for the 40 year-old cohort than the older cohorts because they are less likely to die 
during the time horizon of the model.  Estimated mean QALYs fall as prevalence 
increases because a greater proportion of the cohort experiences the adverse 
health effects of OAG.   
The model was sensitive to the annual costs for visual impairment (VI).  The 
higher the annual cost of VI the more likely screening to become cost-effective. 
The thresholds for this to happen are not dissimilar to the costs estimated by 
Meads and Hyde(17) (e.g. annual cost of VI of approximately £7900 for the first 
year and £7700 for subsequent years).   
The more likely people are to have an eye test in the current practice strategy (i.e. 
the comparator), the less likely screening is cost-effective. A relative high 
attendance for eye tests in the current practice setting might explain the 
somewhat counterintuitive results.  
A review of other cost effectiveness evaluations of screening for OAG (13) 
identified only one previous study that attempted to compare an active screening 
strategy with current practice (11).  This study also concluded that screening for 
OAG was not cost-effective.  However, a recently published cost-utility analysis 
of OAG screening in Finland (24) concluded that a screening programme could 
be cost-effective, especially in older groups where prevalence rates are higher.  In 
contrast to the Finnish analysis our model assumes that no one in the cohorts was 
receiving treatment prior to screening or opportunistic case detection.  The net 
effect of relaxing this assumption is unclear. Stopping inappropriate glaucoma 
treatment could make screening more cost-effective. However, care should be 
taken to consider cost and consequences of those individuals identified as 
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inappropriately treated (e.g. raised IOP but no glaucomatous visual field loss). 
Furthermore, if individuals were treated appropriately, there would be no benefit 
from screening and its cost-effectiveness would be lower.  A further factor 
driving the difference between the conclusions of the Finnish study and our work 
was the inclusion by the Finnish study of the costs of visual impairment.  Our 
results were also sensitive to the inclusion of these higher costs.   
One limitation of our study was that the utility associated with treated and 
untreated glaucoma was assumed to be the same.  This ignores any utility loss 
associated with adverse effects of treatment.  Adverse treatment effects are 
estimated to reduce quality of life by between 7 and 11% depending upon 
severity of these effects, as estimated by Burr and colleagues (8). Future studies 
should consider using a measure appropriate for use within an economic 
evaluation in people whose glaucoma has not progressed, both before and after 
treatment has started.   
The systematic review identified insufficient evidence to meaningfully 
distinguish between the variety of tests that might be used in practice.  This led 
to the simplification of the care pathways where the battery of tests used by a 
glaucoma optometrist was represented by a single value for sensitivity and 
specificity of a test.  This and other simplifications (such as the small number of 
stages to represent disease progression) were made following consultation with 
experts.  Further research to develop the model structure and the associated 
parameter values is required.   
Overall, although the evidence on cost-effectiveness should be treated cautiously, 
the results indicate some patient groups where the organisation of targeted 
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screening, i.e. a surveillance programme, might be given further consideration.  
However care pathways would need to be in place for those not eligible for 
screening.  In situations where it might be feasible to organise a service for the 
target population further primary research on the effectiveness and cost-
effectiveness of such a programme is required. A randomised controlled trial is 
the optimal study design  but prior to such a study being undertaken further 
research is needed to develop feasible strategies to identify individuals in ‘at risk’ 
groups and the optimal configuration of screening strategies to maximise 
screening attendance. 
 
5 Conclusion 
General population screening is unlikely to be considered cost effective.  
However, screening for OAG is associated with an ICER that society might be 
willing to pay for particular cohorts of patients, namely, targeted screening for 50 
year-olds at high risk (e.g familiy history and/or black ethnicity) may be 
worthwhile. Results are sensitive to the assumed annual cost of visual 
impairment.  
Further data related to both improving the estimates available for some of the 
parameters in the model but also from a well designed controlled study 
comparing viable screening strategies in the cohorts of patients for whom this 
research has indicated that screening might be potentially cost-effective, are 
required to confirm the findings. 
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TABLES 
 
WEB SITE Box 1 Definitions of glaucoma health states 
No glaucomatous impairment  Under observation as suspect glaucoma but not on 
medication and  no glaucoma visual field defect in either 
eye 
Mild glaucoma On treatment, no binocular visual field loss, unilateral 
glaucoma visual field defect present 
Moderate glaucoma Up to five missed points (< 10decibels[dB]) in the 
binocular central 20 degrees of visual field 
Severe glaucoma Binocular visual field loss below UK driving standard** 
Visual Impairment (includes 
partial sight and blind) 
As per criteria for 'Severe' except binocular visual field 
loss includes both the upper and lower fields of vision 
 
** 6 or more adjoining missed points (< 10dB), and any additional separate missed point(s) OR a 
cluster of 4 or more adjoining missed points (<10dB); either of which is either wholly or partly 
within the central 20 degree superior or inferior hemispheric field. 
 
 
Table 1.a Model parameter inputs 
Probability Value Source 
Distribution, and values 
used to define the 
distribution 
Cohort start age  40 Base case assumption 60 and 75 years old 
Prevalence of 
Glaucoma 0 to 0.2   
Proportion of 
glaucoma mild 0.50 
Lee 2003(15)  
Tielsch 1991(21) 
0.475 and 0.45 for 60 and 75 
years old, respectively 
Proportion of 
glaucoma moderate 0.30 Tielsch 1991(21)  
Proportion of 
glaucoma severe 0.15 Tielsch 1991(21)  
Proportion of visual 
impaired 0.05 Burr 2007(9) 
0.075 and 0.10 for 60 and 75 
years old, respectively 
   
Incidence of glaucoma: Burr 2007(9)  
40 years old 0.0003 Burr 2007(9) Triangular: min=0.0001; likeliest=0.0003; max= 0.0008 
50 years old 0.0003 Burr 2007(9) Triangular: min=0.0001; likeliest=0.0003; max= 0.0008 
60 years old 0.0008 Burr 2007(9) Triangular: min=0.0002; likeliest=0.0008; max= 0.0022 
70 years old 0.00181 Burr 2007(9) 
Triangular: min=0.00068; 
likeliest=0.00181; max= 
0.0044 
80 years old 0.00141 Burr 2007(9) Triangular: min=0.00097; likeliest=0.00141; max= 0.01 
22 
Hernández et al. “Economic evaluation of screening for open angle glaucoma” 
Progression of glaucoma to:   
glaucoma 
moderate 0.25 Burr 2007(9) 
Triangular: min=0.125; 
likeliest=0.25; max= 0. .75 
glaucoma severe 0.11 Burr 2007(9) Triangular: min=0.055; likeliest=0.11; max= 0.33 
visual impaired 0.1 Burr 2007(9) Triangular: min=0.05; likeliest=0.1; max= 0.30 
RR treated-non 
treated 0.65 Burr 2007(9) 
Lognormal. (Mean=-0.43; 
sd=0.148) 
Mortality Various Burr 2007(9)  
Probabilities of having an eye test 
in current practice:   
40 to 59 0.248 Regression analysis on BHPS data(9) Normal. Mean 0.248; s.e.:0.0019142 
60 to 75 0.3769 Regression analysis on BHPS data(9) Normal. Mean 0.3769; s.e.:0.0046524 
75 and over 0.42 Regression analysis on BHPS data(9) Normal. Mean 0.42; s.e.:0.0051359 
Screening 
Acceptance. All 
groups 
0.78 
 Range: min from Rotterdam 
Study(25); Max from Rhondda Valley 
Study(14) 
Triangular: min=0.66; 
likeliest=0.78; max= 0.918 
Optometrist test 
sensitivity 
 
0.32 Tuck 1991(23) Beta: n=1378; r=436 
Optometrist test 
specificity 
 
0.99 Tuck 1991(23) Beta: n=274,228; r=273,614 
Glaucoma 
Optometrist test 
sensitivity 
 
0.73 Azuara Blanco 2007 (6) Beta: n=33, r=24 
Glaucoma 
Optometrist test 
specificity 
 
0.96 Azuara Blanco 2007(6) Beta: n=67, r=64 
Proportion of 
normal with IOP < 
26 
 
0.96 Burr 2007(9) Beta: n=5682, r=5455 
Proportion of 
glaucoma with IOP ≥ 
26 
 
0.35 Burr 2007(9) Beta: n=20, r=7 
Technician further 
test indeterminacy 0.1 Burr 2007(9) Uniform: 0.06-0.20 
Technician further 
test sensitivity 0.8 Assumption Uniform: 0.8 – 1 
Technician further 
test specificity 0.8 Assumption Uniform: 0.8 – 1 
Ophthalmologist test 
sensitivity 1 Assumption None defined 
Ophthalmologist test 
specificity 1 Assumption None defined 
Ophthalmologist 
observation 
proportion 
0.43 
Henson. Manchester Glaucoma 
Optometry scheme 2005 data 
(personal communication D Henson. 
2006) 
Uniform: 0.39 – 0.47 
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Table 1.b Model parameter inputs: costs and utilities  
Costs 
 
Value (£) 
 
Source 
 
Distribution, and values used to 
define the distribution 
Optometrist test 18.39 Department of Health(3) 
Triangular: min=9.20; likeliest=18.39; 
max=27.59 
Ophthalmologist 
diagnosis tests 133 
Scotland National 
Statistics(5) 
Triangular: min=77; likeliest=133; 
max=397 
Glaucoma Mild 
Treatment 420 Traverso 2005(22) 
Triangular: min=210; likeliest=420; 
max=630 
Glaucoma Moderate 
Treatment 473 Traverso 2005(22) 
Triangular: min=236.5; likeliest=473; 
max=709.5 
Glaucoma Severe 
Treatment 376 Traverso 2005(22) 
Triangular: min=188; likeliest=376; 
max=564 
Visual Impairment 
annual cost 669 Traverso 2005(22) 
Triangular: min=585.41; 
likeliest=669; max=752.06 
Screening Invitation 10.45 
NHS Quality 
Improvement 
Scotland(1)* 
Triangular: min=5.23; likeliest=10.45; 
max=15.68 
Glaucoma 
Optometrist test 46.5 Scottish Executive(3)** 
Triangular: min=23.25; 
likeliest=46.50; max=69.75 
Technician IOP tests 10.63 
NHS Quality 
Improvement 
Scotland(1) 
Triangular: min=5.32; likeliest=10.63; 
max=15.95 
Technician 2nd test 10.63 
NHS Quality 
Improvement 
Scotland(1) 
Triangular: min=5.32; likeliest=10.63; 
max=15.95 
Quality of Life Utility 
weight 
Source Distribution, and values used to 
define the distribution 
Normal 1 Assumption None 
Glaucoma Mild 0.8015 Burr 2007(8) Beta, (alpha = 8.2, beta = 2) 
Glaucoma Moderate 0.7471 Burr 2007(8)  Beta, (alpha = 11.4, beta = 3.5) 
Glaucoma Severe 0.7133 Burr 2007(8)  Beta, (alpha = 1.2, beta = 0.4) 
Visual Impaired 0.5350 Developed using data 
from Gupta 2005(12) 
Log-Normal, u = -0.31029, sigma = 
0.16631 
 
* Take into account the cost for national coordination, local health board 
coordination, screening offices and call and recall, development and maintenance 
of call and recall software, and development and maintenance of image capture 
software. 
** The Scottish eye examination includes a full eye examination, visual field, and 
IOP (e.g. with non-contact tonometry), and supplementary exams if clinically 
indicated (e.g. applanation pressures and threshold fields). 
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Table 2 Base Case results: Incremental cost-effectiveness for the selected start age cohorts by prevalence rate 
Prevalence  Strategy 40 year old cohort 60 year old cohort 75 year old cohort 
  Cost (£) QALYs ICER Cost (£) QALYs     ICER Cost (£) QALYs ICER
1.0%           Current practice 257.40 19.231 187.10 12.477 103.47 6.905
           Technician 520.36 19.233 107,938 364.37 12.479 134,060 210.76 6.905 200,028
           GO 617.34 19.234 398,881 430.42 12.479 409,416 250.74 6.905 521,062
2.0%           Current practice 333.89 19.166 232.42 12.438 125.01 6.884
           Technician 608.76 19.170 65,924 418.47 12.440 88,094 238.87 6.885 137,032
           GO 705.86 19.171 240,717 484.79 12.440 264,869 279.22 6.885 350,449
4.0%           Current practice 486.85 19.036 323.06 12.360 168.11 6.843
           Technician 785.57 19.044 39,118 526.67 12.363 55,160 295.11 6.845 89,440
           GO 882.89 19.045 134,460 593.52 12.364 156,016 336.17 6.845 213,985
6.0%           Current practice 639.82 18.906 413.71 12.281 211.20 6.802
           Technician 962.38 18.918 29,051 634.87 12.286 41,963 351.35 6.804 69,757
           GO 1,059.93 18.919 93,416 702.25 12.287 111,083 393.12 6.804 155,507
8.0%           Current practice 792.79 18.777 504.35 12.203 254.30 6.761
           Technician 1,139.19 18.791 23,775 743.07 12.209 34,851 407.58 6.764 58,999
           GO 1,236.97 18.793 71,648 810.98 12.210 86,547 450.08 6.764 123,022
10.0%           Current practice 945.76 18.647 594.99 12.124 297.39 6.720
           Technician 1,316.00 18.665 20,527 851.27 12.132 30,405 463.82 6.723 52,218
           GO 1,414.00 18.667 58,158 919.71 12.133 71,088 507.03 6.723 102,350
ICER = Incremental cost-effectiveness ratio; GO = ‘glaucoma optometrist’ strategy 
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Table 3 Likelihood of a strategy being cost-effective for selected age cohorts start age and screening intervals 
Probabilistic cost-effectives for different threshold values for Society's willingness to pay for a QALY 
(%) 
1% prevalence of OAG 5% prevalence of OAG 
Cohort 
start 
age 
Screening 
Interval 
Strategy 
10,000      20,000 30,000 50,000 10,000 20,000 30,000 50,000
Current practice         100.0% 98.8% 93.9% 78.5% 94.4% 71.5% 50.8% 34.9%
Technician 0.0%        1.2% 5.9% 21.0% 5.4% 27.9% 48.0% 61.3%
3 years 
(Base 
Case)         GO 0.0% 0.0% 0.2% 0.5% 0.2% 0.6% 1.2% 3.8%
Current practice         100.0% 97.1% 88.2% 69.2% 87.6% 58.6% 43.2% 29.2%
Technician 0.0%        2.7% 11.5% 30.1% 12.2% 40.2% 53.3% 60.4%5 years 
GO 0.0%        0.2% 0.3% 0.7% 0.2% 1.2% 3.5% 10.4%
Current practice 99.8% 92.1% 79.1%      56.2% 82.5% 54.3% 40.2% 29.6%
Technician 0.2%        7.7% 20.3% 42.5% 16.7% 42.3% 51.4% 51.1%
40 
10 years 
GO 0.0%        0.2% 0.6% 1.3% 0.8% 3.4% 8.4% 19.3%
Current practice         100.0% 98.4% 92.9% 79.2% 96.4% 79.3% 64.0% 46.1%
Technician 0.0%        1.5% 6.9% 20.2% 3.5% 20.1% 34.7% 50.5%
3 years 
(Base 
Case) GO 0.0%        0.1% 0.2% 0.6% 0.1% 0.6% 1.3% 3.4%
Current practice         100.0% 97.2% 90.0% 74.4% 93.1% 73.3% 56.7% 40.3%
Technician 0.0%        2.7% 9.6% 24.7% 6.7% 25.7% 40.5% 50.8%5 years 
GO 0.0%        0.1% 0.4% 0.9% 0.2% 1.0% 2.8% 8.9%
Current practice         100.0% 95.1% 86.9% 69.3% 88.1% 63.9% 49.3% 34.9%
Technician 0.0%        4.8% 12.7% 29.5% 11.5% 33.6% 44.0% 48.4%
60 
10 years 
GO 0.0%        0.1% 0.4% 1.2% 0.4% 2.5% 6.7% 16.7%
Current practice         100.0% 99.6% 96.1% 88.1% 99.1% 89.8% 78.7% 64.0%
Technician 0.0%        0.4% 3.7% 11.5% 0.9% 9.9% 20.4% 33.8%
3 years 
(Base 
Case) GO 0.0%        0.0% 0.2% 0.4% 0.0% 0.3% 0.9% 2.2%
Current practice         100.0% 99.6% 96.5% 88.1% 98.2% 86.9% 74.5% 59.9%
Technician 0.0%        0.4% 3.5% 11.9% 1.7% 12.4% 24.2% 34.9%5 years 
GO 0.0%        0.0% 0.0% 0.0% 0.1% 0.7% 1.3% 5.2%
Current practice         100.0% 99.1% 94.6% 84.3% 96.1% 82.2% 69.7% 53.8%
Technician 0.0%        0.9% 5.2% 15.1% 3.8% 16.9% 27.9% 37.5%
75 
10 years 
GO 0.0%        0.0% 0.2% 0.6% 0.1% 0.9% 2.4% 8.7%
GO = ‘glaucoma optometrist’ strategy 
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WEB SITE Table 4.a Deterministic and probabilistic analysis results. 
Analyses for a 40 year old cohort with a 10 year screening 
interval and 5% prevalence of OAG 
Strategy Cost (£) QALYs ICER 10,000 20,000 30,000 50,000 
Current practice 563.34 18.971   82.5% 54.3% 40.2% 29.6% 
Technician 703.24 18.978 20,571 16.7% 42.3% 51.4% 51.1% 
GO 744.38 18.979 42,188 0.8% 3.4% 8.4% 19.3% 
 ICER = Incremental cost-effectiveness ratio; GO = ‘glaucoma optometrist’ strategy 
 
WEB SITE Table 4.b Likelihood of a strategy being cost-effective for different 
incidence and progression parameter values. Analyses for a 40 
year old cohort with a 10 year screening interval and 5% 
prevalence of OAG 
Model 
parameter 
PDs 
Parameters* Strategy 
Probabilistic cost-effectives for different 
threshold values for Society's willingness to 
pay for a QALY (%) 
      10,000 20,000 30,000 50,000 
Incidence High Current practice 82.0% 53.9% 40.0% 29.6% 
    Technician 17.0% 42.4% 50.7% 50.0% 
    GO 1.0% 3.7% 9.3% 20.4% 
  Low Current practice 83.6% 55.7% 42.6% 30.6% 
    Technician 15.5% 40.6% 48.2% 49.3% 
    GO 0.9% 3.7% 9.2% 20.1% 
Progression:  High Current practice 78.8% 48.0% 35.2% 23.8% 
Mild to 
Moderate   Technician 20.5% 48.3% 55.3% 54.8% 
    GO 0.7% 3.7% 9.5% 21.4% 
  Low Current practice 82.2% 54.6% 39.2% 27.8% 
    Technician 16.9% 42.4% 51.3% 53.2% 
    GO 0.9% 3.0% 9.5% 19.0% 
Progression:  High Current practice 77.4% 41.2% 28.2% 18.1% 
Moderate to 
Severe   Technician 21.9% 55.2% 62.2% 59.2% 
    GO 0.7% 3.6% 9.6% 22.7% 
  Low Current practice 89.6% 68.2% 52.3% 36.2% 
    Technician 10.1% 30.2% 42.0% 50.8% 
    GO 0.3% 1.6% 5.7% 13.0% 
Progression:  High Current practice 75.8% 46.2% 32.8% 22.3% 
Severe to VI   Technician 23.2% 49.8% 57.4% 55.4% 
    GO 1.0% 4.0% 9.8% 22.3% 
  Low Current practice 86.9% 66.2% 53.1% 41.6% 
    Technician 12.5% 31.4% 39.9% 42.6% 
    GO 0.6% 2.4% 7.0% 15.8% 
GO = ‘glaucoma optometrist’ strategy; VI = visual impairment 
* High SA: the likeliest parameter value for the triangular distribution equal to maximum 
value from base case analysis; maximum value was assumed to be twice the maximum 
used in the base case (truncated if necessary at 1) and the minimum value was assumed 
to be equal to the likeliest value from the base case. 
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Low SA: likeliest parameter value for the triangular distribution equal to the minimum 
value from base case analysis; the maximum was assumed to be the likeliest value from 
the base case (truncated if necessary at 1) and the minimum value was assumed to be 
equal to zero. 
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Figure 1 Markov model for OAG  
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Figure 1 Markov model for OAG  
Circles represent health states while the arrows show the possible directions in 
which individuals could move at the end of each cycle, depending on the 
transition probabilities.  The states considered in the model were those thought 
to reflect care pathways for people with and without glaucoma. The first line 
represents the pathway for undiagnosed individuals while the bottom section of 
the figure reflects glaucoma progression for treated patients. The observation 
state includes individuals considered suspect but without a definite diagnosis. 
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WEB SITE Figure 2 Value of ICERs for alternative visually impaired annual 
costs. Analyses for a 40 year old cohort, 10 year screening 
interval 
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WEB SITE Figure 2 Value of ICERs for alternative visually impaired annual 
costs. Analyses for a 40 year old cohort, 10 year screening 
interval 
 
At 1% OAG prevalence rate, ‘technician’ strategy dominates NS (e.g. ICER ≤ 0) 
for an annual cost of VI of £16,000. ‘Technician’ strategy looks cost effective (e.g. 
ICER ≤ £30,000) for an annual cost of VI of £8,800. At 5% OAG prevalence rate 
‘technician’ strategy dominates NS for an annual cost of VI of £6,000; and G.O. 
dominates ‘technician’ strategy at an annual cost of VI of £11,000. 
Tech = Techinician strategy; CP = Current practice; GO = Glaucoma trained 
optometrist; VI = visual impairment  
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